Hep C showdowns; M&A mania;

Get out your binoculars for FiercePharma's traditional holiday trend-spotting

> Slimdown craze still on, with sales and spinoffs galore. Slim fast? Not necessarily. More

> Will biopharma keep riding that mammoth M&A wave? Short answer's yes. More

> Limited attention span? Focus on these market shake-ups in 2015. More

> Get ready to negotiate, drugmakers: Payers are armed for drug-pricing battle. More

> Continuous manufacturing reaches a turning point. More

Subscribe to FiercePharma >>

The 5 top trends for med tech in 2014

> Merger mania remakes the landscape. More

> Med tech tackles tough problems. More

> The rapid consumerization of med tech. More

> Google goes after med tech, along with other VCs. More

> Reimbursement continues to be a challenge. More

Subscribe to FierceMedicalDevices >>

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.